Common Contracts
52 similar Underwriting Agreement contracts by Fulcrum Therapeutics, Inc., TherapeuticsMD, Inc., Vse Corp, others
Gritstone bio, Inc. 8,333,333 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 13,334,222 Shares of Common Stock Common Warrants to Purchase 21,667,555 Shares of Common Stock (or Pre-Funded Warrants in Lieu Thereof)...Underwriting Agreement • April 2nd, 2024 • Gritstone Bio, Inc. • Biological products, (no disgnostic substances)
Sagimet Biosciences Inc. Series A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • January 23rd, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”) and in the manner contemplated by this Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Series A common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • Immatics N.V. • Biological products, (no disgnostic substances)
Immatics N.V., a public limited company (naamloze vennootschap) under Dutch law (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,925,000 (the “Firm Shares”) of the Company’s ordinary shares, nominal value €0.01 per share (“Ordinary Shares”), and, at the election of the Underwriters, up to 2,388,750 additional Ordinary Shares (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively referred to as the “Shares.”
Myriad Genetics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,470,588 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 970,588 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
MADRIGAL PHARMACEUTICALS, INC. 1,248,098 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 2nd, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations
Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 1,248,098 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”), and (ii) warrants of the Company to purchase 2,048,098 shares of Common Stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants” and, together with the Firm Shares, the “Firm Securities”). As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to 494,429 additional shares of Common Stock (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called t
VSE Corporation Common Stock, par value $0.05 per share Underwriting AgreementUnderwriting Agreement • July 24th, 2023 • Vse Corp • Services-engineering services
VSE Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom RBC Capital Markets, LLC and William Blair & Company, L.L.C. are acting as representatives (the “Representatives” or “you”) an aggregate of 2,475,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 371,250 additional shares (the “Optional Securities”) of common stock, par value $0.05 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
VIKING THERAPEUTICS, INC. Common Stock, par value $0.00001 per share Underwriting AgreementUnderwriting Agreement • March 31st, 2023 • Viking Therapeutics, Inc. • Pharmaceutical preparations
Viking Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 17,242,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 2,586,300 additional shares (the “Optional Securities”) of common stock, par value $0.00001 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”). To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.
Karuna Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations
Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 2,479,391 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 371,908 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • March 9th, 2023 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,823,530 shares (the “Firm Securities”) of Common Stock, par value $0.001 per share (“Stock”) of the Company and, at the election of the Underwriters, up to 1,323,529 additional shares (the “Optional Securities”) of Stock (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
2seventy bio, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 1st, 2023 • 2seventy Bio, Inc. • Pharmaceutical preparations
2seventy bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,869,566 shares (the “Firm Shares”) and, at the election of the Underwriters, up to additional 1,630,434 shares (the “Optional Shares”) of common stock, $0.0001 par value per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • January 18th, 2023 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,615,384 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,442,307 additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Societal CDMO, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • December 13th, 2022 • Societal CDMO, Inc. • Pharmaceutical preparations
Societal CDMO, Inc., a Pennsylvania corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom RBC Capital Markets, LLC is acting as representative (the “Representative” or “you”) an aggregate of 27,841,737 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Securities”).
Ginkgo Bioworks Holdings, Inc. Class A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • November 18th, 2022 • Ginkgo Bioworks Holdings, Inc. • Biological products, (no disgnostic substances) • New York
Ginkgo Bioworks Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriter named in Schedule I hereto (the “Underwriter”) an aggregate of 41,383,877 shares (the “Firm Shares”) and, at the election of the Underwriter, up to 6,207,581 additional shares (the “Optional Shares”) of Class A common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriter elects to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • September 14th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,200,000 additional shares (the “Optional Shares”) of common stock, $0.001 par value per share (“Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”.
Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • August 17th, 2022 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,590,792 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,438,618 additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
LUMIRADX LIMITED Common Shares, par value $0.0000028 per common share Underwriting AgreementUnderwriting Agreement • July 19th, 2022 • LumiraDx LTD • Pharmaceutical preparations • New York
LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [●] common shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional common shares (the “Optional Shares”), par value $0.0000028 per common share (“Common Shares”), of the Company. The Firm Shares and the Optional Shares, that the Underwriters elect to purchase pursuant to Section 2 hereof, are herein collectively called the “Shares.”
Weave Communications, Inc. Common Stock, par value $0.00001 per share Underwriting AgreementUnderwriting Agreement • November 2nd, 2021 • Weave Communications, Inc. • Services-prepackaged software • New York
Weave Communications, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this underwriting agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Common Stock, par value $0.00001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • October 29th, 2021 • Augmedix, Inc. • Services-business services, nec • New York
Augmedix, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 10,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,500,000 additional shares (the “Optional Securities”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”). To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.
Class A Common Stock Underwriting AgreementUnderwriting Agreement • October 27th, 2021 • Aris Water Solutions, Inc. • Oil & gas field services, nec • New York
Aris Water Solutions, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 17,650,000 shares of Class A common stock, par value $0.01 per share (“Stock”) of the Company, subject to the terms and conditions stated in this Agreement and, at the election of the Underwriters, up to 2,647,500 additional shares of Stock. The aggregate of 17,650,000 shares to be sold by the Company are herein called the “Firm Shares” and the aggregate of 2,647,500 additional shares to be sold by the Company are herein called the “Optional Shares.” The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
Underwriting AgreementUnderwriting Agreement • September 20th, 2021 • Cue Health Inc. • Laboratory analytical instruments • New York
Cue Health Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of common stock, par value $0.00001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Underwriting Agreement September 14, 2021Underwriting Agreement • September 17th, 2021 • Par Technology Corp • Calculating & accounting machines (no electronic computers) • New York
PAR Technology Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 892,857 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 89,286 additional shares (the “Optional Securities”) of common stock, par value $0.02 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Ambrx Biopharma Inc. American Depositary Shares Underwriting AgreementUnderwriting Agreement • June 14th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • New York
Ambrx Biopharma Inc., an exempted company incorporated in the Cayman Islands (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representatives (the “Representatives”), an aggregate of [•] American Depositary Shares representing [•] ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of the Company (the “Firm ADSs”) and, at the election of the Underwriters, up to [•] additional American Depositary Shares representing [•] Ordinary Shares (the “Optional ADSs”). The Firm ADSs and the Optional ADSs that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “ADSs”).
Lyell Immunopharma, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • June 9th, 2021 • Lyell Immunopharma, Inc. • Pharmaceutical preparations • New York
Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 25,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock,” and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to 3,750,000 additional shares (the “Optional Shares”) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Recro Pharma, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • May 13th, 2021 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
Recro Pharma, Inc., a Pennsylvania corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 13,333,333 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,999,999 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
Maxar Technologies Inc. 10,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 22nd, 2021 • Maxar Technologies Inc. • Radio & tv broadcasting & communications equipment • New York
Maxar Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (collectively, the “Underwriters”) an aggregate of 10,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,500,000 additional shares (the “Optional Securities”) of Common Stock, par value $0.0001 per share, of the Company (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Underwriting AgreementUnderwriting Agreement • March 19th, 2021 • Primoris Services Corp • Water, sewer, pipeline, comm & power line construction • New York
Primoris Services Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,500,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 675,000 additional shares (the “Optional Securities”) of common stock, $0.0001 par value per share (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
ThredUp Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • March 3rd, 2021 • ThredUp Inc. • Retail-catalog & mail-order houses • New York
ThredUp Inc., a Delaware corporation (the "Company"), proposes, subject to the terms and conditions stated in this agreement (this "Agreement"), to issue and sell to the several Underwriters named in Schedule I hereto (the "Underwriters"), for whom Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. are acting as representatives (the "Representatives"), an aggregate of [_____] shares and, at the election of the Underwriters, up to [____] additional shares of Class A Common Stock, par value $0.0001 ("Stock") of the Company. The aggregate of [_______] shares to be sold by the Company are herein called the "Firm Shares" and the aggregate of [______] additional shares to be sold by the Company are herein called the "Optional Shares". The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the "Shares".
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 16th, 2021 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto, if any (the “Underwriters”), for whom Cantor Fitzgerald & Co. is acting as representative (the “Representative”, “you” or “your”), an aggregate of 59,459,460 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 8,918,919 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
VSE Corporation Common Stock, par value $0.05 per share Underwriting AgreementUnderwriting Agreement • February 2nd, 2021 • Vse Corp • Services-engineering services • New York
VSE Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. and Canaccord Genuity LLC are acting as representatives (the “Representatives” or “you”) an aggregate of 1,428,600 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 214,290 additional shares (the “Optional Securities”) of common stock, par value $0.05 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
CytomX Therapeutics, Inc. 14,285,714 Shares of Common Stock $0.00001 par value Underwriting AgreementUnderwriting Agreement • January 25th, 2021 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (the “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 14,285,714 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,142,857 additional shares (the “Optional Shares”) of Common Stock of the Company, par value $0.00001 per share (the “Stock”) (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2020 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom Cantor Fitzgerald & Co. is acting as representative (the “Representative”, “you” or “your”), an aggregate of 23,437,500 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 3,515,625 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Tractor Supply Company $650,000,000 1.750% Senior Notes Due 2030 Underwriting AgreementUnderwriting Agreement • October 28th, 2020 • Tractor Supply Co /De/ • Retail-building materials, hardware, garden supply • New York
Tractor Supply Company, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $650,000,000 principal amount of the 1.750% senior notes due 2030 (the “Securities”).
Lithia Motors, Inc. Class A Common Stock (no par value) Underwriting AgreementUnderwriting Agreement • October 5th, 2020 • Lithia Motors Inc • Retail-auto dealers & gasoline stations • New York
Lithia Motors, Inc., an Oregon corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,181,819 shares (the “Securities”) (the “Firm Securities”) and, at the election of the Underwriters, up to 477,272 additional shares (the “Optional Securities”) of Class A Common Stock, no par value per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Underwriting AgreementUnderwriting Agreement • July 24th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,952,381 Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to 892,857 additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
Underwriting AgreementUnderwriting Agreement • June 4th, 2020 • Glu Mobile Inc • Services-computer programming services • New York
If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or “group” (within the meaning of Section 13(d)(3) of the Exchange Act), other than a natural person, entity or “group” (as described above) that has executed a Lock-Up Agreement in substantially the same form as this Lock-Up Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.
